Skip to main content
Fig. 2 | Malaria Journal

Fig. 2

From: Efficacy and safety of artemether–lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial

Fig. 2

Day-7 plasma lumefantrine concentration among malaria-HIV-co-infected patients who had quantifiable concentrations above the lower limit of quantification (n = 85). Day-7 plasma lumefantrine concentration in malaria-HIV-co-infected patients who experienced malaria recurrence day 42 (n = 13) and those who did not experience recurrence day 42 (n = 72) in the intention-to-treat population. Individuals with unquantifiable or missing day-7 lumefantrine concentrations (n = 30), a participant who withdrew consent before day 7 and individuals with lumefantrine values below the lower limit of quantification [< 50 ng/mL] (n = 36) are excluded from the plot. Lumefantrine concentrations are given in ng/mL on a logarithmic scale. Red line is equivalent to 200 ng/mL. Black line through the dot indicates median and the bar represents the interquartile range

Back to article page